PHASE-1 TRIAL OF CHLOROZOTOCIN

  • 1 January 1979
    • journal article
    • research article
    • Vol. 63  (1) , 17-20
Abstract
Chlorozotocin was given to 37 patients with advanced malignant tumors in a daily .times. 5 schedule at 6 wk intervals. Total i.v. doses for each course ranged 75-200 mg/m2. Myeolsuppression was dose-limiting, with a platelet count depression regularly observed at doses of .gtoreq. 150 mg/mg2; leukopenia occurred only at the highest dose level. Nausa and vomiting were mild and uncommon. No hyperglycemia or adverse drug-related effects on renal or hepatic function were observed. No major antitumor activity occurred; however, 3 patients with renal cell carcinoma and 1 patient each with lung cancer, ovarian carcinoma, and Hodgkin''s disease had minor objective decreases in tumor size. A dose range of 150-200 mg/m2 i.v. for each 5-day course is recommended for phase II studies.

This publication has 0 references indexed in Scilit: